CA3024113A1 - Heterocyclic compounds as kinase inhibitors - Google Patents

Heterocyclic compounds as kinase inhibitors Download PDF

Info

Publication number
CA3024113A1
CA3024113A1 CA3024113A CA3024113A CA3024113A1 CA 3024113 A1 CA3024113 A1 CA 3024113A1 CA 3024113 A CA3024113 A CA 3024113A CA 3024113 A CA3024113 A CA 3024113A CA 3024113 A1 CA3024113 A1 CA 3024113A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
cancer
arb
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3024113A
Other languages
English (en)
French (fr)
Inventor
Tong Wang
Stephen Gately
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Drug Development LLC
Original Assignee
Translational Drug Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Drug Development LLC filed Critical Translational Drug Development LLC
Publication of CA3024113A1 publication Critical patent/CA3024113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3024113A 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors Abandoned CA3024113A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562163369P 2015-05-18 2015-05-18
US62/163,369 2015-05-18
US201562203070P 2015-08-10 2015-08-10
US62/203,070 2015-08-10
PCT/US2016/033111 WO2016187324A1 (en) 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3024113A1 true CA3024113A1 (en) 2016-11-24

Family

ID=57320732

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024113A Abandoned CA3024113A1 (en) 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors

Country Status (9)

Country Link
US (3) US10392402B2 (https=)
EP (1) EP3297437A4 (https=)
JP (1) JP2018515623A (https=)
CN (1) CN107835637A (https=)
AU (1) AU2016264220A1 (https=)
CA (1) CA3024113A1 (https=)
HK (1) HK1248070A1 (https=)
IL (1) IL255750A (https=)
WO (1) WO2016187324A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
JP2018515623A (ja) * 2015-05-18 2018-06-14 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としての複素環式化合物
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
EP3541806A4 (en) 2016-11-21 2020-07-01 Translational Drug Development, LLC HETEROCYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
WO2019210008A1 (en) 2018-04-24 2019-10-31 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
JP7688633B2 (ja) * 2019-11-15 2025-06-04 武漢朗来科技発展有限公司 Ｒｏｃｋ阻害剤及びその製造方法と用途
JP7531379B2 (ja) 2019-12-31 2024-08-09 財團法人工業技術研究院 βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用
WO2021142006A1 (en) * 2020-01-07 2021-07-15 Disarm Therapeutics, Inc. Inhibitors of sarm1
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
EP4376840A4 (en) 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
KR20240176853A (ko) * 2023-06-15 2024-12-26 현대자동차주식회사 이중 전원 공급 장치, 그를 포함한 시스템 및 그 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US20110052562A1 (en) 2007-12-19 2011-03-03 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
WO2009126635A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2011130740A2 (en) * 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2702055A1 (en) * 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
JP2018515623A (ja) * 2015-05-18 2018-06-14 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としての複素環式化合物

Also Published As

Publication number Publication date
US20200017520A1 (en) 2020-01-16
HK1248070A1 (zh) 2018-10-12
US20180141959A1 (en) 2018-05-24
IL255750A (en) 2018-01-31
US10633393B2 (en) 2020-04-28
US10392402B2 (en) 2019-08-27
EP3297437A4 (en) 2019-02-27
EP3297437A1 (en) 2018-03-28
JP2018515623A (ja) 2018-06-14
WO2016187324A1 (en) 2016-11-24
AU2016264220A1 (en) 2018-01-04
US20200255448A1 (en) 2020-08-13
CN107835637A (zh) 2018-03-23

Similar Documents

Publication Publication Date Title
US10633393B2 (en) Heterocyclic compounds as kinase inhibitors
US10807966B2 (en) Heterocyclic compounds as kinase inhibitors
AU2006299428B2 (en) Pyrimidine amide compounds as PGDS inhibitors
CA2441501C (en) Rho-kinase inhibitors
CN107406426B (zh) 作为rock抑制剂的环状脲类
CA3144548A1 (en) Heterocyclic compounds as inhibitors of kras g12c
WO2002076976A2 (en) Rho-kinase inhibitors
US20130150364A1 (en) Heterocyclic compound
BR112015012571B1 (pt) Compostos de imidazopiridina e usos terapêuticos dos mesmos
CA2844469C (en) N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
CA2688326C (en) Tetrahydroisoquinolin-1-one derivative or salt thereof
CA2863517A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
AU2009312032A1 (en) Carbamate compound or salt thereof
JP6756962B2 (ja) Ｐｉ３ｋ阻害剤とするピラゾロピリミジン化合物、該化合物を使用する医薬組成物と医薬、および該化合物を調製する方法
CA3168222A1 (en) Pyrrolopyrimidine derivatives and pharmaceutical composition for preventing or treating protein kinase-related disease comprising the same as an active ingredient
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
CN101933926A (zh) 作为pkc抑制剂的吲哚基马来酰亚胺衍生物
KR20060135035A (ko) 유사분열 키네신 억제제
CA3183661A1 (en) Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas
CN118084935A (zh) 咪唑烷酮类化合物及其制备方法与应用
CA3218159A1 (en) Rip1 modulators including azetidine cyclic ureas, preparations, and uses thereof
CA3193415A1 (en) Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof
HK40013991A (en) Heterocyclic compounds as kinase inhibitors
HK1247927B (zh) 组合物、用途及其制备方法
HK1061030B (en) Rho-kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210510

FZDE Discontinued

Effective date: 20231120